13.01.2010 - Shionogi Receives Marketing and Manufacturing Approval of a Novel Anti-viral Drug for Influenza, “RAPIACTA 300mg Bag for Intravenous Drip Infusion” and “RAPIACTA 150mg Vial for Intravenous Drip Infusion”
13 Jan 2010
13.01.2010 Shionogi Receives Marketing and Manufacturing Approval of a Novel Anti-viral Drug for Influenza
© Shionogi B.V. 2020. All rights reserved. This website is owned by Shionogi B.V. Registered with the Trade Register of the Dutch Chamber of Commerce under number 73229180. Registered address is Kingsfordweg 151, 1043GR, Amsterdam, the Netherlands.
Report Side Effect
Just to let you know, you are now moving to another website this is not under our control and Shionogi Limited is not responsible for its contents.